Collegium Pharmaceutical (COLL) Upgraded at BidaskClub

BidaskClub upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a sell rating to a hold rating in a report issued on Wednesday morning.

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald set a $35.00 price objective on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Friday, September 21st. HC Wainwright restated a buy rating on shares of Collegium Pharmaceutical in a research note on Monday, September 17th. ValuEngine downgraded shares of Collegium Pharmaceutical from a strong-buy rating to a buy rating in a research note on Monday, July 2nd. Janney Montgomery Scott set a $27.00 price objective on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Monday, August 6th. Finally, Piper Jaffray Companies set a $34.00 price objective on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Wednesday, July 11th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $31.71.

Shares of Collegium Pharmaceutical stock traded down $0.07 during midday trading on Wednesday, hitting $16.95. The company had a trading volume of 311,040 shares, compared to its average volume of 527,767. The company has a market cap of $489.69 million, a price-to-earnings ratio of -6.86 and a beta of 0.43. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94. Collegium Pharmaceutical has a 1-year low of $9.01 and a 1-year high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.02. The business had revenue of $73.10 million for the quarter, compared to the consensus estimate of $72.21 million. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The company’s revenue was up 1930.6% on a year-over-year basis. As a group, research analysts forecast that Collegium Pharmaceutical will post -1.49 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Atria Investments LLC acquired a new stake in Collegium Pharmaceutical during the second quarter worth $201,000. Cubist Systematic Strategies LLC acquired a new stake in Collegium Pharmaceutical during the second quarter worth $213,000. EagleClaw Capital Managment LLC acquired a new stake in Collegium Pharmaceutical during the first quarter worth $220,000. Stifel Financial Corp acquired a new stake in Collegium Pharmaceutical during the first quarter worth $224,000. Finally, Barclays PLC boosted its stake in Collegium Pharmaceutical by 113.3% during the first quarter. Barclays PLC now owns 10,757 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 5,713 shares in the last quarter. Hedge funds and other institutional investors own 93.57% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Recommended Story: Analyst Ratings

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply